[Clinical efficacy and pregnancy outcomes of fertility-preserving re-treatment after recurrence of the patient with atypical endometrial hyperplasia and early stage endometrial carcinoma]
- PMID: 32074769
- DOI: 10.3760/cma.j.issn.0529-567X.2020.01.005
[Clinical efficacy and pregnancy outcomes of fertility-preserving re-treatment after recurrence of the patient with atypical endometrial hyperplasia and early stage endometrial carcinoma]
Abstract
Objective: To analyze the clinical efficacy and pregnancy outcomes of fertility- preserving re-treatment in patients with recurrent atypical endometrial hyperplasia (AEH) and early stage endometrial carcinoma (EEC) after achieved complete remission (CR) of primary fertility-preserving therapy. Methods: There were 104 cases of AEH and EEC collected from 9 hospitals in the multi-center research network platform of fertility-preserving therapy of endometrial carcinoma in China from January 2005 to May 2019. Thirth-one cases of them relapsed from four hospitals mentioned above,who achieved CR after primary fertility-preserving therapy,was analyzed retrospectively. Of the 31 cases, 27 cases chose fertility-preserving re-treatment. The demographic characteristics, re-treatment effect, clinical factors and pregnancy outcomes were observed. Results: (1) There were 16 AEH cases and 11 ECC cases among 27 recurrent patients who chose fertility-preserving therapy again. After re-treatment, CR was found in 13 out of 16 cases of AEH and 9 out of 11 cases of EEC. The overall CR rate was 81% (22/27). (2) After CR of recurrence, 5 cases (23%, 5/22) of re-recurrence were found after with a median time of 33 months (range 21-80 months). There were 4 cases underwent comprehensive surgical staging, and 1 patient chose the third round of fertility preservation therapy with fully informed consent, and CR was reached after 15 months. (3) There were 16 cases with pregnancy intention, with a total of 12 pregnancies, including 5 cases were natural pregnancy and 7 cases were assisted reproductive technology pregnancy. There were 5 live births. The follow-up time was up to May 2019, and the median follow-up time was 73 months (range 0-123 months). All 27 patients had disease free survival. Conclusions: Recurrent patients with AEH and EEC after achieving successful fertility-preserving therapy could choose fertility-preserving therapy again with comprehensive assessment and fully informed consent. After re-treatment, there is a certain tumor CR rate and pregnancy rate, while the close follow-up is required during treatment.
目的： 探讨子宫内膜非典型增生（AEH）及早期子宫内膜癌（EEC）经保留生育功能治疗达到完全缓解（CR），复发后再次保留生育功能治疗的临床疗效及妊娠结局。 方法： 收集2005年1月—2019年5月全国子宫内膜癌保留生育功能多中心研究网络平台中9家三级甲等医院收治的AEH和EEC患者共104例，整理其中经保留生育功能治疗达到CR后复发的31例患者（来自其中4家医院）的临床病理资料。31例复发患者中，再次接受保留生育功能治疗者27例，回顾性分析其复发后的病理类型、疗效、肿瘤结局及妊娠结局。 结果： （1）27例复发后再次保留生育功能治疗的患者中，AEH 16例、EEC 11例；再次保留生育功能治疗后22例达到CR（81%，22/27），其中AEH和EEC的CR率分别为13/16和9/11。（2）22例复发治疗后达CR的患者中，5例（23%，5/22）再复发，两次复发的中位间隔时间为33个月（21~80个月），其中4例行全面分期手术，1例在充分知情的情况下坚决选择第3轮保留生育功能治疗，15个月后达CR。（3）27例复发后再次保留功能治疗的患者中，有妊娠意愿者16例，共有12例妊娠，妊娠率为12/16。其中，5例为自然妊娠、7例为辅助生殖技术治疗后妊娠；5例足月妊娠，共分娩5例新生儿，活产率为5/12。随访截至2019年5月，中位随访时间为73个月（0~123个月），27例复发后再次接受保留生育功能治疗的患者均无瘤生存。 结论： 经保留生育功能治疗达到CR后复发的AEH和EEC患者，在全面评估病情和患者充分知情同意下，可以选择再次保留生育功能治疗；再次治疗仍具有一定的CR率和妊娠率，但治疗期间须严密观察。.
Keywords: Endometrial hyperplasia; Endometrial neoplasms; Fertility preservation; Neoplasm recurrence, local; Pregnancy outcome; Progestins.